Amino substituted pyrazines as inhibitors or protein kinases

US8436171B2 · kind B2 · utility

Assignee

• Akinion Pharmaceuticals AB · SE

Inventors

• Annika Jensen · Uppsala, SE
• Fredrik Lehmann · Knivsta, SE
• Erik Nordling · Danderyd, SE
• Vendela Parrow · Uppsala, SE

Key dates

• Filing date: Jan 28, 2009
• Grant date: May 7, 2013
• Expiry date: Jun 1, 2029

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to compounds of the general formula (I) wherein R1, R2 and R3 are as defined herein, which can act as inhibitors of protein kinases, specially the Fms-like tyrosine kinase 3 (FLT3). A species illustrative of members of the general formula isThe invention also relates to the use of the compounds in therapy, pharmaceutical compositions comprising the compounds and the use of the compounds for the preparation of a medicament for the prophylaxis and treatment of hematological malignancies, such as AML, MLL, T-ALL, B-ALL and CMML, myeloproliferative disorders, other proliferative disorders like cancer, autoimmune disorders and skin disorders like psoriasis and atopic dermatitis.